Cargando…

Silybin supplementation during HCV therapy with pegylated interferon-α plus ribavirin reduces depression and anxiety and increases work ability

BACKGROUND: Hepatitis C virus infection and interferon treatment are often associated with anxiety, depressive symptoms and poor health-related quality of life. To evaluate the Silybin-vitamin E-phospholipids complex effect on work ability and whether health related factors (anxiety and depression)...

Descripción completa

Detalles Bibliográficos
Autores principales: Malaguarnera, Giulia, Bertino, Gaetano, Chisari, Giuseppe, Motta, Massimo, Vecchio, Michele, Vacante, Marco, Caraci, Filippo, Greco, Carmela, Drago, Filippo, Nunnari, Giuseppe, Malaguarnera, Michele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5109776/
https://www.ncbi.nlm.nih.gov/pubmed/27842532
http://dx.doi.org/10.1186/s12888-016-1115-z
_version_ 1782467604905984000
author Malaguarnera, Giulia
Bertino, Gaetano
Chisari, Giuseppe
Motta, Massimo
Vecchio, Michele
Vacante, Marco
Caraci, Filippo
Greco, Carmela
Drago, Filippo
Nunnari, Giuseppe
Malaguarnera, Michele
author_facet Malaguarnera, Giulia
Bertino, Gaetano
Chisari, Giuseppe
Motta, Massimo
Vecchio, Michele
Vacante, Marco
Caraci, Filippo
Greco, Carmela
Drago, Filippo
Nunnari, Giuseppe
Malaguarnera, Michele
author_sort Malaguarnera, Giulia
collection PubMed
description BACKGROUND: Hepatitis C virus infection and interferon treatment are often associated with anxiety, depressive symptoms and poor health-related quality of life. To evaluate the Silybin-vitamin E-phospholipids complex effect on work ability and whether health related factors (anxiety and depression) were associated with work ability in subjects with chronic hepatitis C treated with Pegylated-Interferon-α2b (Peg–IFN) and Ribavirin (RBV). METHODS: Thirty-one patients (Group A) with chronic hepatitis and other 31 subjects in Group B were recruited in a randomized, prospective, placebo controlled, double blind clinical trial. Group A received 1.5 mg/kg per week of Peg–IFN plus RBV and placebo, while Group B received the same dosage of Peg–IFN plus RBV plus association of Silybin 94 mg + vitamin E 30 mg + phospholipids 194 mg in pills for 12 months. All subjects underwent to laboratory exams and questionnaires to evaluate depression (Beck Depression Inventory - BDI), anxiety (State-trait anxiety inventory - STAI) and work ability (Work ability Index - WAI). RESULTS: The comparison between group A and group B showed significant differences after 6 months in ALT (P < 0.001), and viremia (P < 0.05), after 12 months in ALT (P < 0.001), and AST (P < 0.001), at follow up in AST (P < 0.05), and ALT (P < 0.001). Significant difference were observed after 1 month in WAI (p < 0.001) and BDI (P < 0.05), after 6 months in WAI (P < 0.05) and STAI (P < 0.05), after 12 months and at follow up in WAI, STAI and BDI (p < 0.01). CONCLUSIONS: The supplementation with Silybin-vitamin E -phospholipids complex increased work ability and reduced depression and anxiety in patients treated with Peg–IFN and RBV. TRIAL REGISTRATION: NCT01957319, First received: September 25, 2013. Last updated: September 30, 2013 (retrospectively registered).
format Online
Article
Text
id pubmed-5109776
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-51097762016-11-28 Silybin supplementation during HCV therapy with pegylated interferon-α plus ribavirin reduces depression and anxiety and increases work ability Malaguarnera, Giulia Bertino, Gaetano Chisari, Giuseppe Motta, Massimo Vecchio, Michele Vacante, Marco Caraci, Filippo Greco, Carmela Drago, Filippo Nunnari, Giuseppe Malaguarnera, Michele BMC Psychiatry Research Article BACKGROUND: Hepatitis C virus infection and interferon treatment are often associated with anxiety, depressive symptoms and poor health-related quality of life. To evaluate the Silybin-vitamin E-phospholipids complex effect on work ability and whether health related factors (anxiety and depression) were associated with work ability in subjects with chronic hepatitis C treated with Pegylated-Interferon-α2b (Peg–IFN) and Ribavirin (RBV). METHODS: Thirty-one patients (Group A) with chronic hepatitis and other 31 subjects in Group B were recruited in a randomized, prospective, placebo controlled, double blind clinical trial. Group A received 1.5 mg/kg per week of Peg–IFN plus RBV and placebo, while Group B received the same dosage of Peg–IFN plus RBV plus association of Silybin 94 mg + vitamin E 30 mg + phospholipids 194 mg in pills for 12 months. All subjects underwent to laboratory exams and questionnaires to evaluate depression (Beck Depression Inventory - BDI), anxiety (State-trait anxiety inventory - STAI) and work ability (Work ability Index - WAI). RESULTS: The comparison between group A and group B showed significant differences after 6 months in ALT (P < 0.001), and viremia (P < 0.05), after 12 months in ALT (P < 0.001), and AST (P < 0.001), at follow up in AST (P < 0.05), and ALT (P < 0.001). Significant difference were observed after 1 month in WAI (p < 0.001) and BDI (P < 0.05), after 6 months in WAI (P < 0.05) and STAI (P < 0.05), after 12 months and at follow up in WAI, STAI and BDI (p < 0.01). CONCLUSIONS: The supplementation with Silybin-vitamin E -phospholipids complex increased work ability and reduced depression and anxiety in patients treated with Peg–IFN and RBV. TRIAL REGISTRATION: NCT01957319, First received: September 25, 2013. Last updated: September 30, 2013 (retrospectively registered). BioMed Central 2016-11-15 /pmc/articles/PMC5109776/ /pubmed/27842532 http://dx.doi.org/10.1186/s12888-016-1115-z Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Malaguarnera, Giulia
Bertino, Gaetano
Chisari, Giuseppe
Motta, Massimo
Vecchio, Michele
Vacante, Marco
Caraci, Filippo
Greco, Carmela
Drago, Filippo
Nunnari, Giuseppe
Malaguarnera, Michele
Silybin supplementation during HCV therapy with pegylated interferon-α plus ribavirin reduces depression and anxiety and increases work ability
title Silybin supplementation during HCV therapy with pegylated interferon-α plus ribavirin reduces depression and anxiety and increases work ability
title_full Silybin supplementation during HCV therapy with pegylated interferon-α plus ribavirin reduces depression and anxiety and increases work ability
title_fullStr Silybin supplementation during HCV therapy with pegylated interferon-α plus ribavirin reduces depression and anxiety and increases work ability
title_full_unstemmed Silybin supplementation during HCV therapy with pegylated interferon-α plus ribavirin reduces depression and anxiety and increases work ability
title_short Silybin supplementation during HCV therapy with pegylated interferon-α plus ribavirin reduces depression and anxiety and increases work ability
title_sort silybin supplementation during hcv therapy with pegylated interferon-α plus ribavirin reduces depression and anxiety and increases work ability
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5109776/
https://www.ncbi.nlm.nih.gov/pubmed/27842532
http://dx.doi.org/10.1186/s12888-016-1115-z
work_keys_str_mv AT malaguarneragiulia silybinsupplementationduringhcvtherapywithpegylatedinterferonaplusribavirinreducesdepressionandanxietyandincreasesworkability
AT bertinogaetano silybinsupplementationduringhcvtherapywithpegylatedinterferonaplusribavirinreducesdepressionandanxietyandincreasesworkability
AT chisarigiuseppe silybinsupplementationduringhcvtherapywithpegylatedinterferonaplusribavirinreducesdepressionandanxietyandincreasesworkability
AT mottamassimo silybinsupplementationduringhcvtherapywithpegylatedinterferonaplusribavirinreducesdepressionandanxietyandincreasesworkability
AT vecchiomichele silybinsupplementationduringhcvtherapywithpegylatedinterferonaplusribavirinreducesdepressionandanxietyandincreasesworkability
AT vacantemarco silybinsupplementationduringhcvtherapywithpegylatedinterferonaplusribavirinreducesdepressionandanxietyandincreasesworkability
AT caracifilippo silybinsupplementationduringhcvtherapywithpegylatedinterferonaplusribavirinreducesdepressionandanxietyandincreasesworkability
AT grecocarmela silybinsupplementationduringhcvtherapywithpegylatedinterferonaplusribavirinreducesdepressionandanxietyandincreasesworkability
AT dragofilippo silybinsupplementationduringhcvtherapywithpegylatedinterferonaplusribavirinreducesdepressionandanxietyandincreasesworkability
AT nunnarigiuseppe silybinsupplementationduringhcvtherapywithpegylatedinterferonaplusribavirinreducesdepressionandanxietyandincreasesworkability
AT malaguarneramichele silybinsupplementationduringhcvtherapywithpegylatedinterferonaplusribavirinreducesdepressionandanxietyandincreasesworkability